Despite uncertainty around who will sit in The White House in January and what ramifications they may bring, the industry’s pipeline remains flush with many late-stage therapies showing promising data and transformative potential.
Pipeline Report 2023: Game on for blockbusters, novel MOAs and practice-changing drugs
The industry awaits a number of readouts and approvals for drugs that address market gaps and enrich treatment landscapes — with huge sales potential to boot.
Health systems and pharmaceutical companies will increasingly be relied upon to push back against the effects of surging temperatures and extreme weather events. Are they up to the task?
Pipeline Report 2022: Patient experience takes center stage
The past two years were all about COVID-19 vaccines and therapeutics. Now, imminent approvals in oncology, hematology and autoimmune disorders are set to enhance patient convenience.
Pipeline Report: Several blockbuster drugs are poised to go bigger and broader
COVID vaccines and therapeutics receive all the headlines — with good reason — but the pharma pipeline is bursting with A-grade candidates across a range of conditions.
Biogen’s touted Alzheimer’s drug receives thumbs-down from FDA advisory panel